Skip to main content
  • Register
  • Help
  • Contact us

Genedrive appointed to PHE microbiology supply framework

Mon 19 April 2021 12:07 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - Molecular diagnostics company Genedrive has been successful with its tender to Public Health England (PHE) under Lot 1 of the National Microbiology Framework for diagnostic goods and services, it announced on Monday.

The AIM-traded firm said the tender was opened in November, and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of diagnostic goods and services, covering clinical laboratory diagnostic testing services.

It said the award of a framework contract was not exclusive to the company, nor was it a guarantee of orders, however it would allow participating authorities to issue call-off orders for products in the future.

All of Genedrive's currently-available and CE-marked products fall within the framework agreement, being the Genedrive 96 SARS-CoV-2 kit, the Genedrive HCV ID kit and the Genedrive MT-RNR1 ID kit.

"We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts," said chief executive officer David Budd.

"This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues."

At 1146 BST, shares in Genedrive were up 9.18% at 73.15p.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More AIM news from ShareCast

    No results were found